Clinical significance of circulating tumour cells and tumour marker detection in the chemotherapeutic evaluation of advanced colorectal cancer. (23rd October 2021)

• Record Type: Journal Article
• Authors: Shen, Feifei; Zhu, Yiwen; Wang, Fan; Cai, Xun; Ding, Honghua; Zhou, Fei; Wang, Jingjue; Gu, Hongli; Liu, Chuan; Li, Qi
• Is Part Of: Colorectal disease. Volume 24:Number 1(2022)
• Page Start: 68
• Page End: 76
• Publication Date: 2021-10-23
• Subjects: colorectal cancer -- CTCs -- tumour markers; Colon (Anatomy) -- Diseases -- Periodicals; Rectum -- Diseases -- Periodicals; 616.34
• DOI: 10.1111/codi.15939
• Languages: English
• ISSNs: 1462-8910

Abstract

Abstract: Aim: Systemic chemotherapy combining biological targeted therapies is the standard therapy for patients with metastatic colorectal cancer (mCRC), but effective markers are needed to identify clinical responders. Circulating tumour cells (CTCs) have been associated with prognosis in patients with mCRC. This study aimed to explore the relationship between CTC number and the clinical response of patients with advanced CRC. Method: Epithelial cell adhesion molecule‐independent enrichment and CD45 − fluorescence in situ hybridization immunofluorescence were used to detect peripheral blood CTCs in 79 patients with advanced CRC. Fisher's exact test and Spearman's rank correlation coefficient were used to analyse the correlation between CTC number and efficacy of chemotherapy. Kaplan–Meier and Cox regression analyses were used to evaluate progression‐free survival (PFS). Results: Among the evaluable patients, CTCs were significantly correlated with clinical response ( r =4.891, p = 0.031). High CTC numbers were associated with a poor treatment response ( r = −0.250, p = 0.027). Dynamic decrease in CTC number was associated with clinical response ( p = 0.046). High baseline CTC number and carcinoembryonic antigen levels were prognostic factors for unfavourable PFS in multivariable analysis [hazard ratio (HR) = 3.30, p = 0.011 and HR = 2.04, p = 0.044, respectively]. Compared with the CTC‐positive group, the CTC‐negative group showed superior PFS (median PFS 15.53 vs. 9.43 months, p = 0.041) among CRC patients receiving first‐line treatment. Conclusion: CTC number is a feasible biomarker for predicting outcomes in mCRC patients receiving systemic chemotherapy.